A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study) - A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study)

Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 500 人开始时间: 2015年12月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Synchronous double or multiple cancer or metachronous double or multiple cancer with progression free period less than 5 years. 2) Infectious disease requiring systemic treatment. 3) Pyrexia of 38 degrees centigrade or higher. 4) During pregnancy, within 28 days of postparturition, or during lactation. 5) Psychological disorder difficult to participate in this clinical study. 6) Receiving continuous systemic corticosteroid or immunosuppressant treatment. 7) Diabetes mellitus uncontrollable with the appropriate treatment. 8) Uncontrollable hypertension. 9) History of unstable angina pectoris or myocardial infarction within 6 months before registration. 10) Positive for serum hepatitis B surface antigen.

发起方

Japan Clinical Oncology Group (JCOG)